Drug
Sage 547
Sage 547: highest development phase Phase 3, developed by Sage Therapeutics, Supernus Pharmaceuticals. 5 trial records tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- Sage Therapeutics, Supernus Pharmaceuticals
Trials
| Drug | Phase | Indication |
|---|---|---|
| SAGE-547 NCT02477618 | Phase 3 | Super-Refractory Status Epilepticus |
| SAGE-547 NCT02277106 | Phase 2 | Essential Tremor |
| SAGE-547 NCT02614547 | Phase 2 | Severe Postpartum Depression |
| SAGE-547 NCT02285504 | Phase 2 | Postpartum Depression |
| SAGE-547 NCT02052739 | Phase 1/2 | Super-refractory Status Epilepticus |
Latest
No recent events.
Follow Sage 547 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.